Characteristics of HIV infected adolescents in Latin America: Results from the NISDI pediatric study

Journal of Tropical Pediatrics

Volumn 57, Issue 3, 2011, Pages 165-172

  Cruz, Maria Leticia Santos ^a   Hance, Laura Freimanis ^b   Korelitz, James ^b   Aguilar, Adriana ^c   Byrne, Julianne ^b   Serchuck, Leslie K ^d   Hazra, Rohan ^d   Worrell, Carol ^d  

^a HOSPITAL DOS SERVIDORES DO ESTADO   (Brazil)

^b WESTAT   (United States)

^c Reanimación de Buenos Aires   (Argentina)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Cohort study; HIV infected adolescents; Latin America

Indexed keywords

PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE SEVERITY; DISEASE TRANSMISSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PEDIATRICS; SCHOOL CHILD; SOUTH AND CENTRAL AMERICA; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ARGENTINA; BRAZIL; CHILD; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEXICO; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79957842667     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmq068     Document Type: Article

References (28)

1. Grubman S, Gross E, Lerner-Weiss N, et al. Older children and adolescents Living with perinatally acquired human immunodeficiency virus infection. Pediatrics 1995;95:657-63.
2. Rogers AS, Futterman D, Levin L, D'Angelo L. A profile of human immunodeficency virus-infected adolescents receiving health care services at selected sites in the United States. J Adolesc Health 1996; 19:401-8.
3. Frederick T, Thomas P, Mascola L, et al. Human immunodeficiency virus-infected adolescents: A descriptive study of older children in New York City, Los Angeles County, Massachusetts and Washington DC. Pediatr Infect Dis J 2000;19:551-5.
4. MS -Ministério da Saúde 2010. Departamento de DST/ AIDS e Hepatites Virais. Boletim Epidemiológico. http://www.aids.gov.br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B83FFC9B6-630E-4915-A51C-42E165CDDD82%7D/Boletim2010.pdf. (28 June 2010, date last accessed).
5. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. The Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA 2000;284:190-7.
6. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. New Engl J Med 2001;345:1522-8.
7. Matida LH, Marcopito LF, Succi RC, et al. Improving survival among Brazilian children with perinatally acquired AIDS. Braz J Infect Dis 2004;8:419-23.
8. Patel K, Hernán MA, Williams PL, et al. for the Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: A 10-year follow-up study. Clin Infect Dis 2008;46:507-15.
9. Tovo PA, Gabiano C, Palomba E, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Lancet 1992;339:1249-53.
10. Thorne C, Newell ML, Botet FA, et al. for the European Collaborative Study. Older children and adolescents surviving with vertically acquired HIV infection. JAIDS 2002;29:396-401.
11. Ferrand RA, Corbetta EL, Wood R, et al. AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS 2009;23:2039-46.
12. WHO. Child and Adolescent Health and Development Progress Report 2008 [Online] Geneva, Switzerland: World Health Organization, 2008. http://www.who.int/child-adolescent-health/documents/pdfs/iatt-hivandyoungpeople-overview.pdf. (14 June 2010, date last accessed).
13. Schutt-Aine J, Maddaleno M. Sexual health and development of adolescents and youth in the Americas: Program and policy implications [Online]. Washington, DC: PAHO, 2003. http://www.paho.org/English/HPP/HPF/ADOL/SRH.pdf. (16 June 2010, date last accessed).
14. Hazra R, Stoszek SK, Freimanis Hance L, et al. Cohort Profile: NICHD International Site Development Initiative (NISDI): a prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries. Int J Epidemiol 2009;38:1207-14.
15. Schmid J, Jensen-Fangel S, Valerius NH, et al. Demographics in HIV-infected children in Denmark: Results from the Danish Paediatric HIV Cohort Study. Scand J Infec Dis 2005;37:344-9.
16. CDC. 1993 Revised case definition of AIDS defining conditions for adults and adolescents 13 years of age and older. MMWR December 18, 1992/41 (RR-17).
17. CDC. 1994 Revised classification system for HIV in children less than 13 years of age. MMWR Recomm Rep 1994;43:1-19.
18. Persaud D, Chandwani S, Rigaud M, et al. Delayed recognition of human immunodeficiency virus infection in pre-adolescent children. Pediatrics 1992;90:688-91.
19. Malvy D, Thiébeaut R, Marimoutou C, et al. Weight loss and body mass index as predictors of HIV disease progression to AIDS in adults. Aquitaine Cohort, France, 1985-1997. J Am Col Nutr 2001;20:609-15.
20. Guidelines for the use of antiretroviral agents in pediatric HIV infection, supplement II: Managing complications of HIV infection in HIV-infected children on antiretroviral therapy. 23 February 2009 [Online]. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. http://www.aidsinfo.nih.gov. (24 March 2009, date last accessed.
21. Frederick T, Mascola L, Eller A, et al. Progression of human immunodeficiency virus disease among infants and children infected perinatally with HIV or through neonatal blood transfusion. Pediatr Infect Dis J 1994;13:1091-7.
22. Rogers AS, Futterman D, Moscicki AB, et al. for the Adolescent Medicine HIV/AIDS Research Network. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health 1998;22:300-11.
23. Souza E, Santos N, Valentini S, et al. Long-term follow-up outcomes of perinatally HIV-infected adolescents: Infection control but school failure. J Trop Pediatr 18 February 2010 [Epub ahead of print; doi:10.1093/tropej/fmq008].
24. Murphy DA, Sarr M, Durako SJ, et al. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med 2003;157:249-55.
25. Murphy DA, Belzer M, Durako SJ, et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005;159:764-70.
26. Flynn PM, Rudy BJ, Lindsey JC, et al. Long-term observation of adolescents initiating HAART therapy: Three-year follow-up. AIDS Res Hum Retrov 2007;23:1208-14.
27. Flynn PM, Rudy BJ, Douglas SD, et al. and the Pediatric AIDS clinical Trial Group 381 Study Team. Virologic and immunologic outcomes after 24 Weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis 2004;190:271-9.
28. NCHS. Use and interpretation of the CDC growth charts. Atlanta, GA: National Center for Health Statistics, Centers for Disease Control and Prevention, 2008. http://www.cdc.gov/nccdphp/dnpa/growthcharts/resources/index.htm. (28 June 2010, date last accessed).